Protalix BioTherapeutics Inc.
PLX
Get informed when a big investor buys or sells
+ FollowMarket Cap$170.01M
Close$
$-2.48
226.5% downside
Current Fair Value
226.5% downsideOvervalued by 226.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $170.01 Million |
|---|---|
| Enterprise Value | $136.78 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.08 |
| Beta | -0.01 |
| Outstanding Shares | 79,848,892 |
Return
| Return on Equity | 22.81% |
|---|---|
| Return on Assets | 14.98% |
| Return on Invested Capital | 20.33% |
Valuation & Multiples
| P/E Ratio | 10.99 |
|---|---|
| PEG | -1.81 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.79 |
| Enterprise Value to EBIT | 8.98 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$11.50 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$12.95 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5186▼ 110.49% |
|---|---|
| Total Calls | 260,500▲ 1432.35% |
| Total Puts | 135,100▲ 389.49% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 21.20%▲ 2.40% |
|---|---|
| Total Invested | $36.11M▲ 34.57% |
| Investors Holding | 105▲ 21.00% |
ESG Score
No data
About Protalix BioTherapeutics Inc.
CEO: Dror Bashan